Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Manage cookies
Accept & continue
  • Sign In
  • Subscribe
Open drawer menuOpen search bar
Financial Times
myFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
    Most Read
    • Japan on course for technical recession, economists warn
    • Cambridge caught in crossfire of US-China tech war
    • Hong Kong toilet roll heist underscores coronavirus panic-buying
    • Coronavirus forces Apple to warn over iPhone sales
    • Coronavirus fears force China into mass chicken cull
  • US
    Sections
    • US Home
    • US Economy
    • US Politics & Policy
    • US Companies
    Most Read
    • Smartwatches call time on the Swiss industry
    • Mark Zuckerberg: Big Tech needs more regulation
    • US solar industry powers ahead as investors back batteries
    • Coronavirus forces Apple to warn over iPhone sales
    • Donald Trump’s erratic style of diplomacy has a price
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • SoftBank investment chief pushes hedge fund after Vision Fund stumbles
    • Deutsche Bank faces departures over contractor pay cut
    • Indian IT industry head accuses US of discrimination over worker visas
    • US solar industry powers ahead as investors back batteries
    • Hedge fund Lansdowne hit by failed bet on UK recovery
  • Tech
  • Markets
    Sections
    • Markets Home
    • fastFT
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    Most Read
    • Markets not live, Monday 17th February 2020
    • Further reading
    • Former Morgan Stanley president slams Europe’s capital markets
    • New head of Sonatrach is an opportunity for Algeria
    • Foreign investors in row over Lebanese debt
  • Graphics
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Instant Insight
    • Lex
    • Alphaville
    • Obituaries
    • Letters
    Most Read
    • Smartwatches call time on the Swiss industry
    • Mark Zuckerberg: Big Tech needs more regulation
    • Donald Trump’s erratic style of diplomacy has a price
    • Ireland’s political mess rooted in QE house price fallout
    • The revenge of the middle-class anti-elitist
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • A life on film: how a City executive’s story came to the big screen
    • Quitting a job does not make you a failure
    • Why corporate schmoozing will survive the coronavirus crisis
    • Building success in a highly volatile economy
    • ‘Welcome, friends! I’m Pippa, Thrust’s Vibe-master!’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Smaller buy-to-let landlords sell up 
    • The revenge of the middle-class anti-elitist
    • Vail’s ‘lift line apocalypse’ — and the new ski resort with a radical solution
    • Pot of gold: could you be a cannabis farmer?
    • Where to book a business meal in London
  • How to Spend It
  • Sign In
  • Subscribe
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Graphics
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
  • Sign In
  • Subscribe

Get a fresh start.

Choose your FT trial

Hannah Kuchler

US pharma and biotech correspondent
Hannah Kuchler reports on pharma, biotech and healthcare. After covering Silicon Valley for over five years, she's now focusing on how technology is transforming our health.
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Friday, 14 February, 2020
    Coronavirus
    Mask mania: coronavirus sparks scramble for face covers

    Outbreak exposes reliance on Chinese production of low-cost item as demand surges

  • Wednesday, 12 February, 2020
    Teva Pharmaceutical Industries Ltd
    Teva sees higher margins, lower debt from restructuring

    Drugmaker’s shares rise after earnings give hope that two-year overhaul will pay off

  • Wednesday, 12 February, 2020
    Coronavirus
    Drugmakers braced for coronavirus disruption to supplies

    Chief of India’s Cipla warns of Chinese lockdown cutting off access to essential ingredients

  • Monday, 10 February, 2020
    Drugs research
    Roche and Eli Lilly drugs fail ‘inherited’ Alzheimer’s trial

    Setback deals another blow to most common hypothesis about causes of the disease

  • Monday, 10 February, 2020
    Coronavirus
    Coronavirus sparks hectic trading in search of treatment

    Investors have bid up companies even though potential vaccine is distant

  • Friday, 7 February, 2020
    AbbVie Inc
    AbbVie boosts outlook despite competition from generics

    Quarterly earnings beat expectations as cancer drug sales jump

  • Wednesday, 5 February, 2020
    Biogen Idec Inc
    Biogen shares soar after patent victory

    Mylan had lodged dispute over a drug for multiple sclerosis

  • Wednesday, 5 February, 2020
    Merck & Co Inc
    Merck to spin off assets in effort to streamline its business

    New company with $6.5bn in revenue will include women’s health unit and legacy brands

  • Friday, 31 January, 2020
    Lunch with the FT
    Crispr scientist on the ethics of editing humans

    Her gene-editing tool could cure disease and change the human race. But what happens if it falls into the wrong hands?

  • Promoted Content
  • Thursday, 30 January, 2020
    Coronavirus
    The scientist leading the coronavirus vaccine race

    Pharmaceutical companies work to repurpose existing genetic technology

  • Sunday, 26 January, 2020
    Sport
    Basketball legend Kobe Bryant dies in helicopter crash

    LA Lakers star and daughter among 9 killed when aircraft went down on Sunday

  • Thursday, 23 January, 2020
    US opioid epidemic
    Opioid executive admits to ‘no morals’ ahead of prison term

    Ex-Insys sales chief spoke to FT before former staff were sentenced this week

  • Monday, 20 January, 2020
    AnalysisThe Big Read
    Can we ever trust Google with our health data?

    The technology company will need to persuade patients to hand over some of their most personal information

  • Monday, 20 January, 2020
    GlaxoSmithKline PLC
    GSK and genetic testing group 23andMe seek first drug target

    UK drugmaker hopes to launch clinical trial by end of the year

  • Sunday, 12 January, 2020
    Pharmaceuticals sector
    Start-up proposes ‘third way’ to cut US drug prices

    Alexis Borisy secures $200m funding for venture aiming to use ‘fast follow’ treatments

  • Tuesday, 7 January, 2020
    AnalysisPharmaceuticals sector
    Crispr puts first human in-body gene editing to test

    Companies will seek to restore sight and cure liver condition by using technology like a drug

  • Friday, 3 January, 2020
    Drug prices
    Pfizer and other drugmakers start 2020 with price rises

    Average 6% increase is less than in previous years as industry faces political pressure

  • Thursday, 2 January, 2020
    Tobacco
    US health officials unveil e-cigarette restrictions

    Critics complain policy targeting some flavoured cartridges does not go far enough

  • Wednesday, 1 January, 2020
    Google Inc
    Google AI system beats doctors in breast cancer tests

    Algorithm reduces both false positives and false negatives

  • Wednesday, 18 December, 2019
    Drug prices
    White House lays out plan to import drugs from Canada

    Trump plan focuses on campaign issue while decrying impeachment

  • Tuesday, 17 December, 2019
    US opioid epidemic
    Sacklers withdrew $10bn from Purdue during past decade

    Some states have targeted family members in opioid lawsuits after company bankruptcy

  • Friday, 13 December, 2019
    Health
    Sperm start-ups bet on declining male fertility

    ‘Mick Jagger is probably our biggest enemy,’ says semen test entrepreneur

  • Monday, 9 December, 2019
    Pharmaceuticals sector
    Sanofi buys cancer-focused biotech for $2.5bn

    Drugs group unveils tighter strategic vision as Merck also acquires oncology biotech

  • Monday, 9 December, 2019
    Special ReportFT Health: Regenerative Medicine
    Gene editing heralds new era of animal-to-human transplants

    Biotechs race to serve patients stuck on waiting lists for organs

  • Thursday, 5 December, 2019
    Dementia
    Biogen divulges more data on Alzheimer’s trials

    Biotech’s shares fluctuate as it tries to win over sceptics of aducanumab

Previous You are on page 1 Next

Useful links

Support

View Site TipsHelp CentreAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacyCookiesCopyrightSlavery Statement & Policies

Services

FT LiveShare News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingContracts & Tenders
Executive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubMBA Rankings
Enterprise ToolsNews feedNewslettersCurrency Converter
More from the FT Group
Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2020. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
  • US
    • US Economy
    • US Politics & Policy
    • US Companies
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • fastFT
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
  • Graphics
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Instant Insight
    • Lex
    • Alphaville
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • EM Squared
  • Lunch with the FT
  • FT Globetrotter
  • Tech Scroll Asia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In